Evidence map›Paper›PMID 33552971›Full record

ArticleFrontiers in oncology2020

Use of Simvastatin, Fibrin Clots, and Their Combination to Improve Human Ovarian Tissue Grafting for Fertility Restoration After Anti-Cancer Therapy.

Roei Magen, Yoel Shufaro, Yair Daykan, Galia Oron, Elena Tararashkina, Shulamit Levenberg, Eli Anuka, Avi Ben-Haroush, Benjamin Fisch, Ronit Abir

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed, 1 pooled it
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 1 synthesis or guideline pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Review
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

Roei MagenInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Yoel ShufaroInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Yair DaykanInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Galia OronInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Elena TararashkinaInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Shulamit LevenbergFaculty of Biomedical Engineering, Technion-Israel Institute of Technology, Haifa, Israel.
Eli AnukaDepartment of Biological Chemistry, The Alexander Silberman Institute of Life Sciences, The Hebrew University of Jerusalem, Jerusalem, Israel.
Avi Ben-HaroushInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Benjamin FischInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Ronit AbirInfertility and IVF Unit, Beilinson Women Hospital, Rabin Medical Center, Petach Tikvah, Israel.
Rabin Medical Center · ILTel Aviv University · ILBen-Gurion University of the Negev · ILHebrew University of Jerusalem · ILTechnion – Israel Institute of Technology · IL

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anticancer treatments, particularly chemotherapy, induce ovarian damage and loss of ovarian follicles. There are limited options for fertility restoration, one of which is pre-chemotherapy cryopreservation of ovarian tissue. Transplantation of frozen-thawed human ovarian tissue from cancer survivors has resulted in live-births. There is extensive follicular loss immediately after grafting, probably due to too slow graft revascularization. To avoid this problem, it is important to develop methods to improve ovarian tissue neovascularization. The study's purpose was to investigate if treatment of murine hosts with simvastatin or/and embedding human ovarian tissue within fibrin clots can improve human ovarian tissue grafting (simvastatin and fibrin clots promote vascularization). There was a significantly higher number of follicles in group A (ungrafted control) than in group B (untreated tissue). Group C (simvastatin-treated hosts) had the highest levels of follicle atresia. Group C had significantly more proliferating follicles (Ki67-stained) than groups B and E (simvastatin-treated hosts and tissue embedded within fibrin clots), group D (tissue embedded within fibrin clots) had significantly more proliferating follicles (Ki67-stained) than group B. On immunofluorescence study, only groups D and E showed vascular structures that expressed both human and murine markers (mouse-specific platelet endothelial cell adhesion molecule, PECAM, and human-specific von Willebrand factor, vWF). Peripheral human vWF expression was significantly higher in group E than group B. Diffuse human vWF expression was significantly higher in groups A and E than groups B and C. When grafts were not embedded in fibrin, there was a significant loss of human vWF expression compared to groups A and E. This protocol may be tested to improve ovarian implantation in cancer survivors.

Indexed as

fertility preservation/restoration for cancer patientsfibrin clotshuman ovarian tissuehuman-specific antibodies for von Willebrand factorimmunodeficient micemouse platelet endothelial cell adhesion moleculesimvastatintransplantation

Identifiers

PMID33552971
PMCPMC7862713
OpenAlexW3122834397

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.